The most recently added clinical trials across every neurology subspecialty — one feed, updated continuously. Get them weekly by email or via RSS.
NBP increased the proportion of patients achieving CBF amelioration at 12 weeks: 55.4% vs 43.9% (adjusted RR 1.32, 95% CI 1.08–1.61, p=0.006; unadjusted RR 1.26, 95% CI 1.04–1.54, p=0.020). No significant differences in…
View trial →Functional independence (mRS 0-2) at 90 days: 49% (340/689) tirofiban vs 43% (299/691) placebo (absolute risk difference 6.1 percentage points, 95% CI 0.8-11.3, p=0.023; adjusted RR 1.15, 95% CI 1.03-1.27, p=0.0092) Symp…
View trial →Trial stopped early for safety after interim analysis Symptomatic intracranial haemorrhage increased in DTAS group: 5/34 (15%) vs 0/42 (0%); adjusted OR 11.0 (95% CI 1.28-1406) Functional independence (mRS 0-2 at 90 days…
View trial →RIC did NOT improve 90-day favourable outcome (mRS 0-2): 68.1% (RIC) vs 71.2% (sham); adjusted RR 0.97, 95% CI 0.87-1.08, p=0.61 Intervention was safe and well-tolerated: SAEs within 180 days 8.3% (RIC) vs 8.7% (sham); n…
View trial →Treatment failure occurred in 68.0% of HOV12020 group vs 61.5% of placebo group (both exceeded the 40% expected placebo event rate) Bayesian analysis showed low posterior probability of benefit, meeting predefined futili…
View trial →Tenecteplase did not improve return to baseline function compared to standard care (71.5% vs 74.8%, RR 0.96) More deaths occurred in the tenecteplase group (4.6% vs 1.1%, adjHR 3.8) Trial stopped early for futility; mino…
View trial →Rituximab was noninferior to ocrelizumab for absence of new/enlarging T2 lesions from month 6-24 (92.2% vs 94.8%; risk difference -2.6 percentage points, 95% CI -9.4 to 4.3; P=0.03 for noninferiority) Relapse rates, disa…
View trial →Dexamethasone did NOT improve the primary outcome of verbal memory at 26 weeks: WMS-IV Auditory Memory Index 71 vs 69 (adjusted difference 1.77, 95% CI –9.57 to 13.12; p=0.76) No significant difference in any secondary c…
View trial →Anti-CD20 therapy markedly lowered relapse incidence rate ratio (IRR 0.02, 95% CI 0.01-0.04) vs pretreatment, outperforming nonspecific immunosuppressants (IRR 0.09, 95% CI 0.07-0.13) and MS DMTs (IRR 0.13, 95% CI 0.06-0…
View trial →First positive phase 3 RCT in ataxia-telangiectasia: levacetylleucine reduced SARA total score by −1·92 vs −0·14 with placebo (linear mixed model treatment effect −1·88, 95% CI −2·70 to −1·06; p
View trial →No significant difference in plasma dopamine between LCE and LB at baseline (P=.744), 90 min (P=.704), or 180 min (P=.750) Both regimens raised dopamine modestly; LCE 76.7 → 91.1 → 90 ng/mL, LB 66.4 → 74.1 → 80.8 ng/mL N…
View trial →Median bilateral upper and lower extremity (ULE) motor scores decreased from 33.0 (IQR 28.0-40.5) at baseline to 21.0 (15.0-25.5) at 3 months post-bilateral treatment, a 32% improvement (IQR 18-52, p
View trial →No deaths, no serious TEAEs, and no treatment discontinuations over 12 weeks; TEAEs more frequent with 6 mg/kg/d (90%) vs 2 mg/kg/d (70%), most commonly GI events and infections Dose-dependent adrenal suppression: 50% of…
View trial →Statistically significant dose response observed for change from baseline in MG-ADL at day 57 (p = 0.031, test of linear trend) TEAE incidence similar between combined nipocalimab and placebo groups (83.3% vs 78.6%) Infe…
View trial →Earlier tofersen initiation (vs ~6-month delayed start) was associated with numerically less 148-week decline in ALSFRS-R (−9.9 vs −13.5 points), %-predicted SVC (−13.8 vs −18.1), HHD megascore (−0.38 vs −0.43), and ALSA…
View trial →Primary endpoint NOT met: median OS not improved over historical control in any arm (trial OS 11.1 mo vs historical 10.8 mo); trial stopped for futility. Pairwise comparisons all non-significant: everolimus vs dasatinib…
View trial →Single oHSV injection induced deep, persistent T cell infiltration into GBM up to >2 years post-treatment (median density 30.4 pre vs 138 cells/mm² post, p=0.0078) CD8/Treg ratio rose from 6.8 pre to 21.1 post (p=0.0042)…
View trial →Primary endpoint (change in FACT-Br Trial Outcome Index at 6 months) was not significant: between-group EMM difference 4.1 points (95% CI −4.4 to 12.6, P=.34) After adjustment for time of death, intervention favored on g…
View trial →IV CGRP (1.5 µg/min x 20 min) triggered a typical IIH headache attack in 7/16 women (44%); no participant developed headache after placebo During the ictal phase after CGRP, 8 cytokines were significantly elevated vs bas…
View trial →IFT significantly reduced pain vs placebo (NRS change: -6.1 vs -2.4; between-group difference -3.8; 95% CI -6.4 to -1.1; p=0.008) Attack frequency within 24 hours was markedly lower with IFT (2.5 ± 5.3 vs 16.1 ± 19.6 att…
View trial →THC + CBD (6% THC + 11% CBD) was superior to placebo for 2-h pain relief (67.2% vs 46.6%; OR 2.85 [1.22–6.65], p=0.016), 2-h pain freedom (34.5% vs 15.5%; OR 3.30 [1.24–8.80], p=0.017), and 2-h most-bothersome-symptom fr…
View trial →Primary endpoint not met: ADAS-Cog13 showed only 11% slowing vs placebo (p=0.607, N=320) in overall early AD population Significant slowing of hippocampal atrophy by 18% (p=0.017, N=290) in overall population Prespecifie…
View trial →Primary outcome NOT met: change in cerebral glucose metabolic rate (FDG-PET SUV, composite hippocampus/medial temporal/posterior cingulate) — adjusted difference −0.17 (95% CI −0.39 to 0.06), P=0.14 Cognitive secondary o…
View trial →Overall, dulaglutide-associated changes in biomarkers or SCI were nonsignificant Participants with baseline NfL ≥56 pg/mL had a dulaglutide-associated 2-year reduction in NfL (−27.4% vs −14.2%; p = 0.003) Participants wi…
View trial →Primary safety endpoint met: SADE rate 6.9% (6/87) at 84 days, well below 25% performance goal (p90% of patients and 86% of physicians reported improvement on Global Impression of Change scales No adverse effects on cogn…
View trial →Bayley-III cognitive composite scores at 24 months were similar between early vigabatrin and placebo groups (no significant difference) No significant differences in overall epilepsy incidence, drug-resistant epilepsy at…
View trial →Median reduction in countable motor seizure frequency: -59.8% with bexicaserin vs -17.4% with placebo Reductions observed across DEE subtypes: Dravet syndrome -74.6%, Lennox-Gastaut syndrome -50.8%, DEE Other -65.5% 60.0…
View trial →